< Back to previous page
Researcher
Max Mazzone
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Mazzone Max (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Mazzone Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → 30 Sep 2022
Projects
1 - 10 of 63
- Targeting the DNA methylation profile of cytotoxic T cells to overcome immunotherapy resistance of pancreatic cancerFrom5 Mar 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding glutamate metabolism in the tumor microenvironment to tackle Immune Checkpoint Blockade (ICB) resistanceFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Role of SLC1A3 in tumor-associated macrophages during immunotherapy resistance onset in breast cancerFrom1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancerFrom1 Jul 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Tackling tumor immunosuppression by reprograming eicosanoid metabolism and signaling in the tumor microenvironmentFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Understanding the roles of the epigenetic machinery in shaping distinct tumor-associated macrophage phenotypes.From10 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Tackling SLC1A3 in tumor-associated macrophages to overcome anti-PD1 immunotherapy resistance in breast cancerFrom31 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- BD Imaging Cell Sorter – BD Cell View TechnologyTMFrom24 Jun 2022 → TodayFunding: Other federal scientific institutions
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
41 - 50 of 179
- Differential Effects of Trp53 Alterations in Murine Colorectal Cancer(2021)
Authors: Max Mazzone
- MicroRNA-Mediated Metabolic Shaping of the Tumor Microenvironment(2021)
Authors: Federico Virga, Max Mazzone
- Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development(2020)
Authors: Maarten Dewilde, Max Mazzone
- Macrophage-derived glutamine boosts satellite cells and muscle regeneration(2020)
Authors: Federica Cappellesso, Federico Virga, Guy Eelen, Bart Ghesquière, Peter Carmeliet, Mario di Matteo, Emanuele Berardi, Max Mazzone
Pages: 626 - + - Hypoxia-induced miR-210 modulates inflammatory response and fibrosis upon acute peripheral ischemia(2020)
Authors: Max Mazzone
Pages: 3755 - 3755 - Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages(2020)
Authors: Max Mazzone
- Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site(2020)
Authors: Max Mazzone
Pages: 1673 - 1697 - B55α/PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling A Complementary Approach To Disrupt Pathological Vessels?(2020)
Authors: Ward Celus, Elizabeth Jones, Max Mazzone
Pages: 707 - 723 - Editorial: Macrophage Metabolism and Immune Responses(2020)
Authors: Max Mazzone
- Understanding Metal Dynamics Between Cancer Cells and Macrophages: Competition or Synergism?(2020)
Authors: Max Mazzone
Patents
1 - 10 of 10
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)
- Biomarker for anti-tumor therapy (Inventor)
- Combination of p2y6 inhibitors and immune checkpoint inhibitors (Inventor)
- Inhibition of slc4a4 in the treatment of cancer (Inventor)
- Means and methods to treat inflammatory diseases (Inventor)
- Glutamine dehydrogenase inhibitors for use in muscle regeneration (Inventor)
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Podoplanin positive macrophages (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)